Celgene (CELG) has been on my watchlist for a while as its shares continue to lag despite the promise of a rich pipeline, high regard of the company among the scientific community, and the continued decline in the share price which has increased my interest in the name.
In January, I wondered if Juno Therapeutics could rejuvenate the pipeline of Celgene, yet this addition came at a sizeable cost of $9 billion, as I held a small long position at the time. I liked the strategy of smaller bolt-on deals in the past, but this large deal and recent operating struggles in the pipeline might suggest that management has become less disciplined in its dealmaking.

